Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NU101
- Development stage
- Unknown
- Lead developer
- Nuclidium
- Modality
- Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NU101 (also known as NuriPro) is a copper-based theranostic radiopharmaceutical program developed by Nuclidium AG for the management of metastatic castration-resistant prostate cancer (mCRPC). The program consists of a diagnostic component, 61Cu-NuriPro (Cu-61-NU101), and a therapeutic component, 67Cu-NuriPro (Cu-67-NU101). Both agents utilize the PSMA I&T ligand conjugated via a NODAGA chelator to target the Prostate-Specific Membrane Antigen (PSMA) expressed on prostate cancer cells. The diagnostic agent leverages the 3.3-hour half-life of Copper-61 to provide high-resolution PET imaging with a broader distribution window than traditional imaging agents. The therapeutic agent uses Copper-67 to deliver targeted beta-particle radiation to tumor sites, aiming to minimize off-target effects while maximizing anti-tumor efficacy. The diagnostic component is currently in Phase 1 clinical trials, while the therapeutic component is expected to enter clinical development in early 2026.
- Brand names
- NuriPro
- Other names
- 61Cu-NuriPro67Cu-NuriPro61Cu-PSMA67Cu-PSMA
02
Targets
1C metabolism (One-carbon metabolism)
Beyond the preview
Go deeper on NU101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NU101.